Munehisa Tsuruta
Kurume University
13 Papers
75 Citations
Munehisa Tsuruta is an academic researcher from Kurume University. The author has contributed to research in topics: Diabetes mellitus & Insulin resistance. The author has an hindex of 5, co-authored 13 publications.
Chat about Author
Papers
Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan
Yuji Tajiri,Munehisa Tsuruta,Tsuyoshi Ohki,Tomoko Kato,Yuko Sasaki,Kayo Tanaka,Shusuke Kono,Masayuki Tojikubo,Kentaro Yamada +8 more
TL;DR: Clinicians should keep in mind that the individual variation of glucose-lowering effects and the possibility of relapsing exist during sitagliptin treatment, and that concern about life-style is still a quite important issue to prevent weight gain and the relapsed of blood glucose control.
32
Hypophosphatemic Osteomalacia Due to Drug-induced Fanconi's Syndrome Associated with Adefovir Dipivoxil Treatment for Hepatitis B
TL;DR: Following dose reduction of ADV and the administration of treatment with calcitriol and phosphates, the patient's serum phosphate level increased and his clinical symptoms improved, and Physicians prescribing ADV should carefully monitor the renal function and serum phosphatelevel.
25
Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
Kentaro Yamada,Hitomi Nakayama,Satoko Yoshinobu,Seiko Kawano,Munehisa Tsuruta,Masayuki Nohara,Rika Hasuo,Shoko Akasu,Ichiro Tokubuchi,Nobuhiko Wada,Saori Hirao,Shinpei Iwata,Hiroo Kaku,Yuji Tajiri +13 more
TL;DR: To assess the effects of sodium glucose co‐transporter 2 inhibitor therapy on the pathophysiology of type 2 diabetes, a large number of patients with type 1 and 2 diabetes were treated with this drug.
24
Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves’ Orbitopathy
Hiroyuki Eguchi,Junichi Tani,Saori Hirao,Munehisa Tsuruta,Ichiro Tokubuchi,Kentaro Yamada,Masataka Kasaoka,Yasuo Teshima,Tatsuyuki Kakuma,Yuji Hiromatsu +9 more
TL;DR: It is suggested that, in patients with GO, evaluation of preexisting risk factors—including viral hepatitis—and careful weekly monitoring of liver function during IVMP therapy and monthly thereafter for 12 months are warranted.
Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report.
Ayako Nagayama,Kenji Ashida,Kanoko Moritaka,Mami Hidaka,Mizuki Gobaru,Seiji Tanaka,Nao Hasuzawa,Shoko Akasu,Yuka Goto,Seiichi Motomura,Kento Hara,Munehisa Tsuruta,Nobuhiko Wada,Hitomi Nakayama,Yuji Tajiri,Masatoshi Nomura +15 more
TL;DR: It is concluded that metreleptin supplementation may be an effective alternative therapy for improving the expected prognosis of patients with acquired incomplete lipodystrophy, including childhood cancer survivors.
9